Skip to main content

Advertisement

SpringerLink
Log in

Combination of surgery and immunotherapy in metastatic renal cell carcinoma

  • Topic Paper
  • Published:
World Journal of Urology Aims and scope Submit manuscript

Abstract

The treatment of choice for non-disseminated renal cell cancer (RCC) is surgery. However, the 5-year survival rates for all stages do not exceed 60%, even in contemporary series. Further improvement will most likely have to await the development of a more effective systemic therapy and the application of combined treatment modalities to counter the relatively high number of patients presenting with advanced stages. Whereas textbook belief up to the 1990s suggested refraining from surgical antitumor-therapy in the case of metastatic RCC, current strategies clearly advocate debulking tumor nephrectomy in the context of modern immunotherapies. This dramatic change of attitude stemmed from two randomized phase III trials conducted by EORTC and SWOG, including a combined analysis of both studies, in which cytoreductive tumor nephrectomy conveyed a significant survival benefit over immunotherapy alone. Concepts and progress in this field appear to be of major interest for modern oncologic urologists following the advent of immunotherapeutic strategies that require surgical intervention at some stage of the treatment cascade.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Mickisch GHJ (2002) Principles of nephrectomy for malignant disease. BJU Int 89:488–495

    Article  CAS  PubMed  Google Scholar 

  2. Mickisch GHJ (2000) Surgical approaches to organ-confined renal cell carcinoma. Onkologie 23:208–212

    Article  Google Scholar 

  3. Mickisch GH, Carballido J, Hellsten S, Schulze H, Mensink H (2001) Guidelines on renal cancer. Eur Urol 40:252–255

    Article  Google Scholar 

  4. Mickisch GH (2004) Salvage surgery for advanced renal cell carcinoma. Europ Urol [Supp 3]:2–8

  5. Mickisch GHJ (1999) Lymph node dissection for renal cell carcinoma—the value of operation and adjuvant therapy. Urologe (A) 38:326–331

    Google Scholar 

  6. Bukowsky RM (1997) Natural history and therapy of metastatic renal cell carcinoma. Cancer 80:1198–1220

    Article  Google Scholar 

  7. Mickisch GHJ (2003) Rational selection of a control arm for randomized trials in metastatic renal cell carcinoma. Eur Urol 43:670–679

    CAS  PubMed  Google Scholar 

  8. Joffe JK, Banks RE, Forbes MA (1996) A phase II study of interferon-a, interleukin-2 and 5-fluorouracil in advanced renal cell carcinoma: clinical data and laboratory evidence of protease activation. Br J Urol 77:638–649

    Article  CAS  PubMed  Google Scholar 

  9. Brussel von J, Mickisch GH (1999) Prognostic factors in renal cell and bladder cancer. Br J Urol 83:902–909

    Google Scholar 

  10. Kavolius JP, Mastorakos DP, Pavlovich C (1998) Resection of metastatic renal cell carcinoma. J Clin Oncol 16:2261–2266

    CAS  PubMed  Google Scholar 

  11. Mickisch GHJ (2002) Multimodality treatment of metastatic renal cell carcinoma. Expert Rev Anticancer Ther 2:681–685

    Google Scholar 

  12. Walther MM, Yang JC, Pass Hl (1997) Cytoreductive surgery before high dose interleukin-2 based therapy in patients with metastatic renal cell carcinoma. J Urol 158:1675–1678

    Google Scholar 

  13. Tigrani VS, Reese DM, Small EJ, Presti JCJr, Carroll PR (2000) Potential role of nephrectomy in the treatment of metastatic renal cell carcinoma: a retrospective analysis. Urology 55:36–40

    Article  CAS  PubMed  Google Scholar 

  14. Bennett RT, Lerner SE, Taub HC (1995) Cytoreductive surgery for stage IV renal cell carcinoma. J Urol 154:32–34

    Article  Google Scholar 

  15. Taneja SS, Pierce W, Figlin R (1995) Immunotherapy for renal cell carcinoma: the era of interleukin-2 based treatment. Urology 45:911–914

    Google Scholar 

  16. Fallick ML, McDermott DF, LaRock D (1997) Nephrectomy before interleukin-2 therapy for patients with metastatic renal cell carcinoma. J Urol 158:1691–1695

    Google Scholar 

  17. Mickisch GH, Garin A, Van Poppel H, De Prijck L, Sylvester R (2001) Radical nephrectomy plus Interferon-alpha based immunotherapy compared with interferon-alpha alone in metastatic renal cell carcinoma: a randomized trial. Lancet 358:966–970

    Article  CAS  PubMed  Google Scholar 

  18. Flanigan RC, Salmon S, Blumenstein BA, Bearman SI, Roy V, McGrath PC, Caton JR, Munshi N, Crawford ED (2001) Nephrectomy followed by interferon alpha-2b compared with interferon alpha-2b alone for metastatic renal cell cancer. N Engl J Med 345:1655–1659

    Article  CAS  PubMed  Google Scholar 

  19. Flanigan RC, Mickisch G, Sylvester R, Tangen C, Poppel von H, Crawford ED (2004) Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 171:1071–1076

    Article  Google Scholar 

  20. Walther MM, Lyne JC, Libutti SK, Linehan WM (1999) Laparoscopic cytoreductive nephrectomy as preparation for administration of systemic interleukin-2 in the treatment of metastatic renal cell carcinoma: a pilot study. Urology 53:496–501

    Article  Google Scholar 

  21. Fleischmann JD, Kim B (1991) Interleukin-2 immunotherapy followed by resection of residual renal cell carcinoma. J Urol 145:938–941

    Google Scholar 

  22. Wagner JR, Walther MM, Linehan WM, White DE, Rosenberg SA (1994) Interleukin-2 based immunotherapy for metastatic renal cell carcinoma with the kidney in place. J Urol 162:43–45

    Article  Google Scholar 

  23. Rackley R, Novick AC, Klein EA (1994) The impact of adjuvant nephrectomy on muItimodality treatment of metastatic renal cell carcinoma. J Urol 152:1399–1403

    Google Scholar 

  24. Krishnamurthi V, Novick AC, Bukowski RM (1998) Efficacy of multimodality therapy in advanced renal cell carcinoma. Urology 51:933–937

    Article  Google Scholar 

  25. Negrier S, Escudier B, Lasset C, Douillard JY, Savary J, Chevreau C, Ravoud A, Mercatello A, Peny J, Mousseau, M, Philip T, Tursz T (2000) Recombinant human interleukin-2, recombinant human interferon Alpha-2a, or both in metastatic renal cell carcinoma. N Engl J Med 338:1272–1278

    Article  Google Scholar 

  26. Atzpodien J, Kirchner H, Illiger HJ, Metzner B, Ukena D, Schott H, Funke PJ, Gramatzki M, Jurgensen S, Wandert T, Patzelt T, Reitz M (2001) Il-2 in combination with IFN-alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial. Br J Cancer 85:1130–1136

    Article  CAS  PubMed  Google Scholar 

  27. Vis AN, Gaast van der A, Rhijn van BWG, Catsburg TK, Schmidt C, Mickisch GHJ (2002) A phase II trial of methotrexate-human serum albumin (MTX-HSA) in patients with metastatic renal cell carcinoma who progressed under immunotherapy. Cancer Chemother Pharmacol 49:342–345

    Article  Google Scholar 

  28. Motzer RJ, Mazumdar M, Bacik J, Russo P, Berg WJ, Metz EM (2000) Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma. J Clin Oncol 18:1928–1935

    Google Scholar 

  29. Medical Research Council Renal Cancer Collaborators (1999) Interferon-a and survival in metastatic renal cell carcinoma: early results of a randomised controlled trial. Lancet 353:301–305

    Google Scholar 

  30. Fossa SD, Mickisch GHJ, DeMulder PHM, Horenblas S, Oosterom van AT, Poppel von H, Fey M, Croles JJ, DePrijck L, Glabbecke van M (2004) Interferon-a-2a with or without 13-cis-retinoic acid in patients with progressive, measurable metastatic renal cell carcinoma. Cancer 101:533–540

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Center of Operative Urology, c/o Academic Hospital Bremen “Links der Weser”, Robert Koch Strasse 34a, 28277 Bremen, Germany

    Gerald H. Mickisch & Roland H. Mattes

Authors
  1. Gerald H. Mickisch
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Roland H. Mattes
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gerald H. Mickisch.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mickisch, G.H., Mattes, R.H. Combination of surgery and immunotherapy in metastatic renal cell carcinoma. World J Urol 23, 191–195 (2005). https://doi.org/10.1007/s00345-004-0468-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00345-004-0468-y

Keywords

Search

Navigation